Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariel Rechtman

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Frontiers in Neurology|December 18, 2025
Brain atrophy in NMOSD and MOGAD: a meta-analysis of volumetric and DTI biomarkersAriel Rechtman, Omri Zveik, Adi Vaknin-Dembinsky
Immunology|January 20, 2024
Anti- and pro-inflammatory milieu differentially regulate differentiation and immune functions of oligodendrocyte progenitor cellsOmri Zveik, Ariel Rechtman, Livnat Brill, et al.
Molecular Neurodegeneration|July 12, 2024
The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cellsOmri Zveik, Ariel Rechtman, Tal Ganz, et al.
Clinical Neurology and Neurosurgery|August 20, 2025
Repeated MRI-negative demyelinating attacks linked to MOG-IgG antibodies and silent lesions - Case series and literature reviewTal Friedman-Korn, Ariel Rechtman, Omri Zveik, et al.
Journal of Neuroimmunology|February 1, 2024
Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSDNitsan Haham, Omri Zveik, Ariel Rechtman, et al.
Journal of Neuroimmunology|May 4, 2024
A protective effect of lower MHC-II expression in MOGADAriel Rechtman, Omri Zveik, Nitsan Haham, et al.
Journal of the Neurological Sciences|January 19, 2024
Thyroid hormone dysfunction in MOGAD and other demyelinating diseasesAriel Rechtman, Omri Zveik, Nitsan Haham, et al.
Journal of Neuroimmunology|July 10, 2022
IL-6 as a marker for NMOSD disease activityAdi Haramati, Ariel Rechtman, Omri Zveik, et al.
Multiple Sclerosis and Related Disorders|September 11, 2025
A predictive model for triple negative optic neuritis patients: Identifying the subset of patients with favorable outcomesAriel Rechtman, Tal Friedman-Korn, Sol Zamir, et al.
Journal of Neurology|May 29, 2024
Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settingsAriel Rechtman, Tal Freidman-Korn, Omri Zveik, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Frontiers in Neurology|December 18, 2025
Brain atrophy in NMOSD and MOGAD: a meta-analysis of volumetric and DTI biomarkersAriel Rechtman, Omri Zveik, Adi Vaknin-Dembinsky
Immunology|January 20, 2024
Anti- and pro-inflammatory milieu differentially regulate differentiation and immune functions of oligodendrocyte progenitor cellsOmri Zveik, Ariel Rechtman, Livnat Brill, et al.
Molecular Neurodegeneration|July 12, 2024
The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cellsOmri Zveik, Ariel Rechtman, Tal Ganz, et al.
Clinical Neurology and Neurosurgery|August 20, 2025
Repeated MRI-negative demyelinating attacks linked to MOG-IgG antibodies and silent lesions - Case series and literature reviewTal Friedman-Korn, Ariel Rechtman, Omri Zveik, et al.
Journal of Neuroimmunology|February 1, 2024
Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSDNitsan Haham, Omri Zveik, Ariel Rechtman, et al.
Journal of Neuroimmunology|May 4, 2024
A protective effect of lower MHC-II expression in MOGADAriel Rechtman, Omri Zveik, Nitsan Haham, et al.
Journal of the Neurological Sciences|January 19, 2024
Thyroid hormone dysfunction in MOGAD and other demyelinating diseasesAriel Rechtman, Omri Zveik, Nitsan Haham, et al.
Journal of Neuroimmunology|July 10, 2022
IL-6 as a marker for NMOSD disease activityAdi Haramati, Ariel Rechtman, Omri Zveik, et al.
Multiple Sclerosis and Related Disorders|September 11, 2025
A predictive model for triple negative optic neuritis patients: Identifying the subset of patients with favorable outcomesAriel Rechtman, Tal Friedman-Korn, Sol Zamir, et al.
Journal of Neurology|May 29, 2024
Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settingsAriel Rechtman, Tal Freidman-Korn, Omri Zveik, et al.
Pageof 3